文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

分子学改变在原发性骨髓纤维化患者移植决策中的作用

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
PubMed 文献 · Blood Adv · 2025-01-01

研究利用一个移植队列(n=241)和一个非移植队列(n=239),检验携带较高风险分子学评分的原发性骨髓纤维化患者能否从造血干细胞移植(HSCT)获益。加权分析显示,HSCT与中危-2和高危DIPSS、高危MIPSS70、高危和极高危MIPSS70+V2患者更高的6年总生存率相关;MIPSS70中危患者仅在骨髓纤维化移植评分系统(MTSS)为低或中危时移植才有生存优势。

要点

  • HSCT与中危-2(60.1% vs 41.5%)和高危DIPSS(44.4% vs 6.55%)患者更高的6年总生存率相关。
  • HSCT与高危MIPSS70(46.5% vs 23.9%)、高危(73.2% vs 39.7%)和极高危MIPSS70+V2(51.8% vs 24%)更高的6年总生存率相关。
  • MIPSS70中危患者仅在MTSS为低或中危时HSCT才有生存优势。

核心结论

  • 本研究证实,与DIPSS类似,MIPSS70和MIPSS70+V2风险评分联合MTSS可用于判断哪些原发性骨髓纤维化患者从HSCT获得的生存获益优于非HSCT策略。

研究设计与样本

  • 研究使用一个移植队列(n=241)和一个非移植队列(n=239),检验较高风险分子学评分患者从HSCT获益的假设。
  • 采用以移植队列为参照的加权倾向评分平衡混杂因素,并进行加权Cox比例风险模型和logistic回归分析。
  • 共105例未接受移植的患者可与239例接受移植的患者匹配。

主要发现

  • HSCT与中危-2(60.1% vs 41.5%)和高危DIPSS(44.4% vs 6.55%)患者更高的6年总生存率相关。
  • HSCT与高危MIPSS70(46.5% vs 23.9%)、高危(73.2% vs 39.7%)和极高危MIPSS70+V2(51.8% vs 24%)患者更高的6年总生存率相关。
  • MIPSS70中危患者仅在MTSS为低或中危时HSCT才有生存优势。
  • 接受移植的患者第一年死亡风险增加,但在1年landmark之后,较高风险患者中观察到HSCT的显著获益。

关键数值与推荐

  • 中危-2 DIPSS:HSCT组6年总生存率60.1% vs 非HSCT组41.5%。
  • 高危DIPSS:HSCT组6年总生存率44.4% vs 非HSCT组6.55%。
  • 高危MIPSS70:HSCT组6年总生存率46.5% vs 非HSCT组23.9%。
  • 高危MIPSS70+V2:HSCT组6年总生存率73.2% vs 非HSCT组39.7%;极高危MIPSS70+V2:HSCT组51.8% vs 非HSCT组24%。

临床怎么用

  • 作者认为,MIPSS70和MIPSS70+V2风险评分联合MTSS可用于判断哪些原发性骨髓纤维化患者从HSCT获得的生存获益优于非HSCT策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of our study was to analyze the potential survival benefit associated with hematopoietic stem cell transplantation (HSCT) according to clinicobiological scores, which incorporate mutation-enhanced international prognostic score system (MIPSS) to facilitate decision-making in this context. One transplant (n = 241) and 1 nontransplant cohort (n = 239) were used to test the hypothesis that patients with primary myelofibrosis with higher risk molecular score benefit from HSCT. A weighted propensity score was applied to balance confounding factors with the transplanted cohort as reference. Weighted Cox proportional hazard models and logistic regression analyses were performed. Overall, 105 patients who did not receive transplant could be matched to the 239 patients who did receive transplants. HSCT was associated with a higher 6-year overall survival rate in intermediate-2 (60.1% vs 41.5%) and high-risk DIPSS patients (44.4% vs 6.55%), high-risk MIPSS70 (46.5% vs 23.9%), high-risk (73.2% vs 39.7%) or very high-risk MIPSS70+V2 (51.8% vs 24%). Patients with intermediate MIPSS70 scores have an advantage of survival with HSCT only when their myelofibrosis transplant scoring system (MTSS) were low or intermediate. Patients who received transplant had an increased mortality risk the first year, but a significant benefit with HSCT after the 1-year landmark was observed in higher risk patients. This study confirms that, similar to DIPSS, MIPSS70 and MIPSS70+V2 risk score in addition to MTSS can be used to determine which patients with primary myelofibrosis have survival benefit from HSCT over non-HSCT strategies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Luque Paz D, Gagelmann N, Benajiba L, et al. Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis. Blood Adv. 2025. PMID: 39561372. doi:10.1182/bloodadvances.2024014368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。